natgillin/translations-raw huggingface dataset:
It is generally preferred to use water which has been purified by processes such as deionization or reverse osmosis, to improve the batch-to-batch formulation inconsistencies which can be caused by dissolved solids in the water supply. 
Općenito je poželjno upotrijebiti vodu koja je pročišćena postupcima kao što su deionizacija ili reverzna osmoza, da se smanje nesukladnosti među šaržama, koje mogu biti uzrokovane otopljenim krutinama u zalihi vode.
A method according to any of the claims 1 to 8, wherein applying said water-free silane-based liquid is done by brushing or rolling said water-free silane-based liquid to the profiled surface. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se nanošenje navedene bezvodne tekućine na bazi silana provodi četkanjem ili valjanjem navedene bezvodne tekućine na bazi silana na profiliranu površinu.
heating said thermally curable, aqueous binder composition at a temperature sufficient to cure the aqueous binder composition. 
(b) zagrijavanje vodene smjese veziva koja se može termički stvrdnuti, na temperaturi koja je dovoljna da stvrdno vodenu smjesu veziva.
The beverage of claim 3, wherein Reb X is present in a concentration from 50 to 600 ppm and Reb B is present in a concentration from 10 to 150 ppm. 
Napitak prema zahtjevu 3, naznačen time da Reb X je prisutan u koncentraciji od 50 do 600 ppm i Reb B je prisutan u koncentraciji od 10 do 150 ppm.
A tablet according to claim 10, wherein the opioid hydrochloride salt comprises at least about 5% (by weight) of said core and said high molecular weight PEO comprises at least about 50% (by weight) of said core. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevu 12, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem 1,000,000.
Binding of IL-18BP to the column material is preferably carried out at pH 9.1±0.2, e.g. 
Vezanje proteina IL-18BP za materijal kolone se poželjno provodi kod pH 9.1 + 0.2 tj.
The delivery system of claim 13, wherein a lubricant is discharged into a throttle body of the internal combustion engine to lubricate a working part within the engine. 
Sustav za dovođenje prema zahtjevu 2, naznačen time da se sredstvo za podmazivanje ispušta u tijelo regulatora za gas motora s unutarnjim izgaranjem radi podmazivanja radnog dijela unutar motora.
The method of any preceding claim, wherein the sum total of the 5' and the 3' homology arms of the LTVEC is from 10 kb to about 20 kb, from about 20 kb to about 40 kb, from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 120 kb, or from about 120 kb to 150 kb. 
Postupak sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da ukupni zbir 5’ i 3’ homologih ruku LTVEC je od 10 kb do oko 20 kb, od oko 20 kb do oko 40 kb, od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 120 kb, ili od oko 120 kb to 150 kb.
The container according to any one of the previous claims, wherein the adhesive is at least partially provided in a depression forming the fluid guide element (16, 17, 18, 36, 37, 38, 39, 40, 41). 
Spremnik u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navodeći element za fluid (16, 17, 18) u obliku linije.
These fusible fibres are, for example, mixed into the slubbings or drawing slivers produced in a normal preliminary spinning stage. 
Ova topljiva vlakna su, na primjer, umiješana u skupine vlakana ili u hladno istezane pramene koji su proizvedeni u normalnom prethodnom stupnju predenja.
The method of claim 13, wherein: the filler is a combination of corn starch and soy protein fines and is present at a concentration of about 30% to about 60% (w/w); the solvent is a mixture of liquid polyethylene glycol and caprylic/capric triglycerides and is present at a concentration of about 5% to about 20% (w/w); 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da: a) punilo je kombinacija kukuruznog škroba i fino mljevenih sojinih proteina i prisutno je u koncentraciji od oko 30% do oko 50% (masa/masa); b) otapalo je mješavina tekućeg polietilenglikola 1 kapriličnih/kapričkih triglicerida 1 prisutno je u koncentraciji od oko 5% do oko 20% (masa/masa):
A modified FIX (factor IX) polypeptide for use in a medical treatment in a daily dosage between 0.1 µg/kg and 400 µg/kg body weight, said modified FIX polypeptide having at least 70% identity with a SEQ ID NO: 1 or SEQ ID NO: 2; wherein leucine is present at a position corresponding to position 338 of an unmodified mature FIX polypeptide as identified by SEQ ID NO: 2. 
Modificirani FIX (faktor EX) pohpeptid za upotrebu u liječenju u dnevnoj dozi između 0.1 mg/kg i 400 me/kg sukladno tjelesnoj težini, naznačeno time, da spomenuti modificirani FIX polipeptid koji ima najmanje 70% identičnosti s SEQ ID NO: 1 iH SEQ ID NO: 2; gdje je leucin prisutan na položaju koja odgovara položaju 338 nemodificiranog zrelog FIX pohpeptida kao što je identificirano sa SEQ ID NO: 2.
at least one disintegrant in an amount within the range of from 3% to 10% by weight; 
(c) najmanje jedno sredstvo za dezintegraciju u količini u rasponu od 3% do 10%, po masi;
The method of claim 1, wherein the disease is ankylosing spondylitis. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest ankilozni spondilitis.
The oral formulation of claim 1, wherein the lubricant is sodium stearyl fumarate. The oral formulation of claim 12, wherein the oral formulation comprises about 2% to about 10% weight percent of sodium stearyl fumarate. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 8, naznačena time što je mazivo 1% do 11%, težinski, magnezijev stearat ili natrijev stearil-fumarat.
The method for waterproofing and draining off seeped water according to claim 1, characterised by performing a drainage valve (13) comprising a geomembrane sheet chosen from the following materials: thermoplastic materials, thermoplastic rubbers, thermoset materials, bituminous materials. 
Postupak za hidroizolaciju i drenažu infiltrirane vode u skladu s patentnim zahtjevom 1, naznačen time, da se koristi ventil za drenažu (13) koji se sastoji od geomembranskih ploča odabranih od sljedećih materijala: termoplastičnih materijala, termoplastičnih guma, termo materijala, bitumenskih materijala.
iii) said second antigen-binding site specifically binding to ANG-2 comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO: 46, a CDR2 region of SEQ ID NO: 47, and a CDR1 region of SEQ ID NO: 48, and in the light chain variable domain a CDR3 region of SEQ ID NO: 49, a CDR2 region of SEQ ID NO: 50, and a CDR1 region of SEQ ID NO: 51; and 
spomenuto drugo mjesto vezivanja antigena, koje se specifično veže na ANG-2, sadrži u varijabilnoj domeni jakog lanca, područje CDR3 od SEQ ID NO:46, područje CDR2 od SEQ ID NO:47; i područje CDR1 od SEQ ID NO:48; a u varijabilnoj domeni slabog lanca, sadrži područje CDR3 od SEQ ID NO:49, područje CDR2 od SEQ ID NO: 50, i područje CDR1 od SEQ ID NO:51; te
A medication delivery device according to claim 1, wherein the adjusted dose is equal to the first dose if the variable B is negative and is equal to the second dose if the variable B is positive. 
Sukladno zaštiti 1, uređaj za davanje lijeka naznačen je time što je prilagođena doza jednaka prvoj dozi ako je varijabla B negativna te je jednaka drugoj dozi ako je varijabla B pozitivna.
Figure 2b is a section through the individual arrangement 1 in its assembled or finished state. 
Slika 2b prikazuje presjek kroz pojedinačnu naprava 1 u njezinom složenom ili završenom stanju.
The use of Claim 13, wherein both a compound of formula I as well as at least one additional therapeutic agent selected from the group consisting of an antidiabetic agent, an anti-obesity agent, a anti-hypertensive agent, an anti-atherosclerotic agent and a lipid-lowering agent, are used in the manufacture of a medicament in the form of a pharmaceutical combination for concurrent or sequential administration of the said compound of formula I and the said at least one additional therapeutic agent. 
Primjena prema patentnom zahtjevu 13, naznačena time što se i spoj formule I kao i najmanje jedno dodatno terapeutsko sredstvo izabrano iz grupe koju čine antidijabetično sredstvo, sredstvo protiv debljine, anti-hipertenzivno sredstvo, anti-arterosklerotsko sredstvo i sredstvo za snižavanje nivoa lipida, koriste u proizvodnji lijeka u obliku farmaceutske kombinacije za istovremenu ili uzastopnu primjenu navedenog spoja formule I i navedenog najmanje jednog dodatnog terapeutskog sredstva.
Cells were grown in T-175 flasks or Costar black, clear-bottomed 96-well view plates and maintained at 37°C in a 90% humidified incubator with an atmosphere of 5% CO2 and 95% air. 
Stanice su rasle u tikvicama T-175 ili pločicama s 96 jamica Costar black, čistog dna i držane su pri 37"C u 90%-tnom vlažnom inkubatoru s atmosferom od 5% CO, 1 95% zraka.
computing a measured signal up by means of the first, second and third currents, 
- < računanje izmjerenog signala u, pomoću prve, druge 1 treće struje,
The vaporizer device of clause 8, wherein the vaporizable substance is selected from the group consisting of a liquid, a wax, or a plant material, and any combination thereof. 
Uređaj za vaporizaciju (100) prema bilo kojem od zahtjeva 1, 2, 4 1 5, naznačen time, da je tvar za vaporizaciju odabrana iz skupine koju čine tekućina, vosak, ili biljni materijal, te bilo koja njihova kombinacija.
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents OR, NRR′ which may form a ring or SR, in which the term “NRR′ forms a ring” means that R and R′ together with the nitrogen atom to which they are attached, to form a saturated nitrogen-containing ring, and in which R and R′ independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms optionally substituted with one or a plurality of alkoxy groups having 1 to 8 carbon atoms, halogen atoms or hydroxyl groups, an aryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, alkoxy groups having 1 to 8 carbon atoms or halogen atoms, or a heteroaryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, an alkoxy groups having 1 to 8 carbon atoms or a halogen atom, 
Ru pri čemu R, predstavlja OR, NRR' koji može tvoriti prsten ili SR, u kojem R i R' neovisno predstavljaju vodikov atom, ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma, halogene atome ili hidroksilne skupine, arilnu skupinu proizvoljno supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogene atome, ili heteroarilnu skupinu po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogeni atom, R, predstavlja vodikov atom, ili ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma, i
methylating the compound according to formula (1), or tautomer, or salt thereof, to obtain a compound according to formula (2), or tautomer, or salt thereof, 
43 b) metilacija spoja prema formuli (1) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2) ili 15
crystallizing the desired composition from the solvent or suspending agent by adding seed crystals in the form of: 
kristalizaciju željenog pripravka iz otapala ili sredstva za suspenziju dodavanjem zametaka kristala u obliku:
The structure according to Claim 1 or Claim 2, characterized in that said lateral walls (315) extend in the stream bed (12) and delimit said flow section (20; 320) limiting it to a partial width of said bed (12) . 
Struktura u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što se navedene bočne stijenke (315) pružaju u koritu vodene struje (12) i omeđuju navedeni dio vodenog toka (20; 320), ograničujući ga na dio širine navedenog korita (12).
use of the compound of the aforementioned (1) in combination with a calcium antagonist or a diuretic agent for manufacture of an agent for the prophylaxis or treatment of circulatory diseases; 
JA gdje R! je kao definiran u zahtjevu 1, ili njegova sol, u kombinaciji s antagonistom kalcija, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
is 1 to 2 amino acid residues in length. Item 20. 
L4 je duljine 1 do 2 ostatka amino kiseline.
Process according to claim 1, wherein in step (d) the acid is chosen from the group consisting of sulfuric acid, phosphoric acid, acetic acid, formic acid, trichloroacetic acid and carbonic acid, the temperature is between 20 and 70° C., the pressure is about 1 bar and that stoichiometric ratio of the acid to alkali used in step (a) is approximately 1.05:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se u koraku (d) kiselina bira iz skupine koju čine sumporna kiselina, fosforna kiselina, octena kiselina, mravlja kiselina, trikloroctena kiselina i ugljična kiselina, temperatura je između 20 1 70%, tlak je otprilike 1 bar (100 kPa), a stehiometrijski omjer između kiseline 1 alkalije u koraku (a) je približno 1,05:1.
The method of any of Embodiments 1 through 11, wherein mixing a lubricating oil with a first portion of a refrigerant to form a mixture comprises mixing the first portion of the refrigerant in a liquid phase with the lubricating oil downstream of a pump circulating the first portion of the refrigerant. 
Postupak prema Zahtjevu 1, gdje miješanje ulja za podmazivanje s prvom količinom rashladnog sredstva kako bi se oblikovala mješavina podrazumijeva miješanje prve količine rashladnog sredstva u tekućoj fazi s uljem za podmazivanje nizvodno od pumpe koja cirkulira prvu količinu rashladnog sredstva.
An extended release tablet formulation, wherein the contained amount of pramipexole or pharmaceutically acceptable salt thereof is sufficient to provide a daily dose administered at one time. 
Formulacija tablete produljenog oslobađanja u skladu s bilo kojim prethodnim zahtjevom, naznačena time, da je sadržana količina pramipeksola ili njegove farmaceutski prihvatljive soli dovoljna da osigura dnevnu dozu primjenjenu odjednom.
When the user equipment is power limited, its power control unit scales the weighted sum of the transmit power for all PUSCH transmissions on the component carriers on which resources have been assigned. 
Terminalni uređaj sukladno zahtjevu 1, naznačen time da kad se pluralitet PUSCH-ova konfigurira na pluralitetu prijenosnika komponenti, sekcija skaliranja skalira snagu za PUSCH prijenos smanjujući zbroj snaga pluraliteta PUSCH-ova.
An inserter according to the claim 3, characterised in that the main part (11) comprises an opening or a slot (12) in a diagonal direction through essentially the whole diameter of the main part (11), adapted to receive at least one removal string (7) of the intrauterine system. 
Aplikator za umetanje prema zahtjevu 3, naznačen time što glavni dio (11) ima otvor ili utor (12) u dijagonalnom smjeru kroz u biti cijeli promjer glavnog dijela (11), prilagođen za primanje barem jedne trake za uklanjanje (7) intrauterinog sustava.
The genetically modified cell of claim 2, wherein the aberrant Hbb gene comprises a point mutation. 
Genetski modificirana stanica prema patentnom zahtjevu 1, naznačena time što donorska sekvenca ispravlja mutaciju točke.
A method according to claim 66, wherein said sludge is sludge from a biological treatment process. 
Metoda u skladu s patentnim zahtjevom 66, pri čemu je navedeni talog talog iz postupka biološke obrade.
bonding a part of the wear resistant particles (15) to the surface (2) with the liquid binder (11), and 
. vezanje dijela čestica otpornih na habanje (15) na površinu (2) s tekućim vezivom (11),
The method of claim 1, wherein the polyurethane based polymer is selected from the group consisting of thermoplastic polyurethane and thermoset polyurethane. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 1, naznačen time što je polimer na bazi poliuretana izabran iz grupe koju čine termoplastični poliuretan i termoreaktivni poliuretan.
A package comprising separate dosage forms according to claim 9 or 10. 
Pakiranje koje sadrži posebne dozirne oblike prema zahtjevu 7 ili 8.
The use according to item 37, wherein said melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is melphalan flufenamide hydrochloride (J1). The use according to item 37 or 38, wherein said excipient is selected from Polysorbate 80 and PEG 400. The use according to any one of items 37-39, wherein said melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in ethanol prior to subjecting said melphalan flufenamide to said excipient. 
Uporaba saharoze, u liofiliziranom pripravku melfalan flufenamid hidroklorida (J1), naznačena time, da je namijenjena za smanjenje vremena rekonstitucije liofiliziranog pripravka melfalan flufenamid hidroklorida (J1), kada se rekonstituira u vodenom otapalu. Uporaba u skladu s patentnim zahtjevom 11, naznačena time, da se spomenuti melfalan flufenamid hidroklorid (J1) otopi u etanolu prije izlaganja spomenutog melfalan flufenamid hidroklorida (11) djelovanju navedene saharoze.
A process according to claim 1 or 2, characterised in that the groove structures (4) are filled with a filling medium which exists in liquid form. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da su brazdaste strukture ispunjene s punilom koje postoji u tekućem obliku.
Hood 128 helps contain the mixture as it moves out of nozzles 12L and 12R, and helps prevent wind or debris from affecting the application. 
Poklopac 128 štiti mješavinu dok izlazi iz mlaznica 12L i 12D, i sprječava da vjetar ili otpaci utječu na nanošenje.
cortisone or hydrocortisone, and/or further energy sources such as e.g. 
kortizona ili hidrokortizona, i/ili druge izvore energije poput pr.
reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of a base to form a salt of the compound of formula (V); and 
reakciju spoja formule (IV), ili njegove soli, s N-hidroksisukcinimidom u prisutnosti baze, da se dobije sol spoja s formulom (V); i
In a process for obtaining a mixture of trifluoroacetyl polypeptides which do not all have the same amino acid sequence, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and trifluoroacetyl lysine, wherein the mixture has a desired average molecular weight and wherein during the process a batch of a mixture of polypeptides, each of which consists essentially of alanine, Y-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetic acid, the improvement comprising use of a solution of hydrobromic acid in acetic acid, which solution comprises less than 0.5% of free bromine. 
Postupak za dobivanje smjese trifluoracetil glatiramer acetata, naznačen time, da se za vrijeme postupka, šarži smjese polipeptida, od kojih se svaki sastoji od alanina, Y-benzil glutamata, tirozina i trifluoracetil lizina, skida zaštita otopinom bromovodične kiseline u octenoj kiselini, kod čega poboljšanje obuhvaća uporabu otopine bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 1000 ppm nečistoća metalnim ionima i manje od 0,5% slobodnog broma.
a contiguous sequence of the human X light chain locus that spans from hVλ3-12 through hVλ3-1; 
(a) susjedne sekvence lokusa humanog lakog 2 lanca koja se proteže od VA3-12 do V23-1;
The immunogenic composition of claim 7 wherein the H. influenzae b capsular saccharide is conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
fumigating the inlet air stream of the compression ignition engine with the fumigant comprising dimethyl ether; 
- < isušivanje struje ulaznog zraka motora s kompresijskim paljenjem s fumigantom koji sadrži dimetil eter;
R1 is absent when ------ is a double bond, or when ------ is a single bond, N1-R1 and one of Ra or Rb are connected to form a saturated, partially unsaturated, or unsaturated heterocycle having 5-7 ring members and the other of Ra or Rb may be hydrogen or absent as necessary to accommodate ring unsaturation; and at least one of the following A-D applies: 
R; je odsutan kada je jednostruka veza, N,-R, i jedan od R, ili R, su povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-7-eročlami heterociklički prsten, a drugi od R, ili R, može biti vodik ili je po potrebi odsutan zbog nezasićenosti prstena; i gdje vrijedi najmanje jedna od slijedećih točaka A-D:
The method according to claim 3, wherein agomelatine is dissolved in an organic solvent before an aqueous HCI solution is added to precipitate a crystal of the product. The method according to claim 4, wherein the aqueous HCl solution is added dropwise. 
Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se agomelatin otopi u organskom otapalu prije dodavanja vodene otopine HCI da se istaloži kristal proizvoda.
The compound or its salt according to claim 6, wherein R1 is alkyl, haloalkyl, cycloalkyl or alkenyl. 
Piridil-triazolopirimidin derivat ili njegova sol prema zahtjevu 2, naznačen time, da je R! alkil, haloalkil, cikloalkil ili alkenil.
The pharmaceutical composition in form of emulsion or microemulsion for use according to claim 8, wherein said at least one lipophilic compound is selected from natural oils, such as almond oil, canola oil, castor oil, corn oil, cottonseed oil, olive oil, safflower oil, sesame oil, soybean oil and the like; fatty acid esters, such as isopropyl palmitate, isopropyl myristate, ethyl oleate and the like; fatty alcohols, such as myristic alcohol, oleyl alcohol and the like; fatty acids, such as myristic acid, oleyl acid, palmitic acid and the like, triglycerides, such as long and/or medium-chain triglycerides and the like; diglycerides and monoglycerides; preferably, said at least one lipophilic compound is medium-chain triglycerides or a natural oil, preferably selected from sesame oil, almond oil and soybean oil. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 10, gdje se taj barem jedan lipofilni spoj odabire između prirodnih ulja, kao što su bademovo ulje, kanola ulje, ricinusovo ulje, kukuruzno ulje, pamučno ulje, maslinovo ulje, ulje šafranike, sezamovo ulje, sojino ulje; estera masnih kiselina, kao što su izopropil palmitat, izopropil miristat, etil oleat; masnih alkohola, kao što su miristinski alkohol, oleinski alkohol; masnih kiselina, kao što su miristinska kiselina, oleinska kiselina, palmitinska kiselina; triglicerida, kao što su dugolančani i/ili srednjelančani trigliceridi; diglicerida i monoglicerida.
The process of embodiment 5, wherein the process includes at least one of the following: 
Postupak u skladu s patentnim zahtjevom 5, pri čemu postupak uključuje najmanje jedno od sljedećeg:
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound cyprodinil. 
CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.